Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Asbury

Allergy & Immunology Bluefield, WV Medical Doctor

NPI 1164529889 CMS profile 188759

500 Cherry St, Bluefield, WV 24701

Open in the dashboard

General payments

$9,487

554 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donald Asbury of Bluefield, WV is reported in the CMS Open Payments database as having received $9,487 across 554 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,693 79
2024 General $1,487 77
2023 General $1,341 75
2022 General $1,126 71
2021 General $1,426 90
2020 General $1,173 75
2019 General $1,241 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Asbury
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Donald Asbury were reported at $1,693. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Donald Asbury Allergy & Immunology median Middle half National median
2019 $1,241 $594 $163–$1,512 $163
2020 $1,173 $426 $106–$1,233 $114
2021 $1,426 $638 $157–$1,708 $132
2022 $1,126 $790 $205–$1,961 $149
2023 $1,341 $852 $220–$2,147 $160
2024 $1,487 $865 $203–$2,267 $164
2025 $1,693 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,186 128 payments
  2. CSL Behring $1,701 95 payments
  3. Regeneron Healthcare Solutions, Inc. $1,448 74 payments
  4. GlaxoSmithKline, LLC. $1,362 89 payments
  5. Genentech USA, Inc. $615 38 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $314 20 payments
  7. Genzyme Corporation $308 18 payments
  8. Novartis Pharmaceuticals Corporation $308 23 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $256 15 payments
  10. Teva Pharmaceuticals USA, Inc. $168 10 payments
  11. Other $819 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,283 549 payments
  2. Education $203 5 payments
Products named General payments · program years 2019–2025
  1. Hizentra $1,050 57 payments
  2. DUPIXENT Inflammation And Immunology $1,033 61 payments
  3. NUCALA $776 50 payments
  4. FASENRA $683 36 payments
  5. Xolair $615 38 payments
  6. DUPIXENT Immunology $614 35 payments
  7. Haegarda $523 32 payments
  8. SPIRIVA RESPIMAT $441 28 payments
  9. DUPIXENT Immunology And Inflammation $414 13 payments
  10. TEZSPIRE $362 20 payments
  11. Other $3,761 228 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

2,597

Median for Allergy/ Immunology: 449

Drug cost

$525,114

Median for Allergy/ Immunology: $169,700

Branded share of claims

35%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 31 $114,670
Xolair Omalizumab Brand 14 $102,899
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 89 $75,926
Breo Ellipta Fluticasone/Vilanterol Brand 69 $35,731
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 30 $33,288
Advair Hfa Fluticasone Propion/Salmeterol Brand 80 $31,349
Symbicort Budesonide/Formoterol Fumarate Brand 58 $22,117
Spiriva Respimat Tiotropium Bromide Brand 16 $17,461
Epinephrine Generic 44 $10,750
Albuterol Sulfate Hfa Albuterol Sulfate Brand 223 $8,497

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$247,191

Of which drugs: $198,254

Medicare patients

189

Average age 72

Services billed

9,334

140 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 42%
Ischemic heart disease 29%
COPD 22%
Chronic kidney disease 21%
Depression 21%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 15 15 $515

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $339
  • GENZYME CORPORATION $71
$410 31 —
Hizentra
  • CSL Behring $245
$245 — —
XOLAIR
  • Genentech USA, Inc. $162
  • Novartis Pharmaceuticals Corporation $43
$204 14 —
NUCALA
  • GlaxoSmithKline, LLC. $165
$165 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $115
  • Amgen Inc. $16
$131 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

554 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record